References
Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Reviews of Infectious Diseases 5(Supp. 3): S428, 1983
Affrime MB, Lowenthal DT. Analgesics, sedatives and sedative-hypnotics. In Anderson et al. (Eds) Clinical use of drugs in patients with liver and kidney disease, pp. 199–210, W.B. Saunders, Philadelphia, 1981
Albert KS, Gernaat CM. Pharmacokinetics of ibuprofen. American Journal of Medicine 76: 40, 1984
Alberts DS, Chang SY, Chen HS, Evans TL, Moon TE. Oral melphalan kinetics. Clinical Pharmacology and Therapeutics 26: 73, 1979
Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clinical Pharmacokinetics 9: 222, 1984
Amdisen A. Serum level monitoring and clinical pharmacokinetics of lithium. Clinical Pharmacokinetics 2: 73, 1977
Amsterdam J, Brunswick D, Mendels J. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. American Journal of Psychiatry 137: 653, 1980
Anderson RJ, Schrier RW, Gambertoglio JG. Clinical use of drugs in patients with kidney and liver disease, W.B. Saunders, Philadelphia, 1981
Antila M, Haatja M, Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. European Journal of Clinical Pharmacology 18: 263, 1980
Aronoff GR, Bergstrom RJ, Bopp RJ, Sloan RS, Callaghan JT. Nizatidine disposition in subjects with normal and impaired renal function. Clinical Pharmacology and Therapeutics 43: 688–695, 1988
Aronoff GR, Szwed JJ, Nelson RL, Marcus EL, Kleit SA. Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. Antimicrobial Agents and Chemotherapy 18: 212, 1980
Aronson JK. Clinical pharmacokinetics of digoxin. Clinical Pharmacokinetics 5: 137, 1980
Bach JF, Dardenne M. The metabolism of azathioprine in renal failure. Transplantation 12: 253, 1971
Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clinical Pharmacokinetics 6: 215, 1981
Balant L, Dayer P, Auckenthalaer R. Clinical pharmacokinetics of the third generation cephalosporins. Clinical Pharmacokinetics 10: 101, 1985
Balis FM, Holcenberg JS, Bleyer WA. Clinical pharmacokinetics of commonly used anticancer drugs. Clinical Pharmacokinetics 8: 202, 1983
Barbeau G, Belanger PM. Pharmacokinetics of nalidixic acid in old and young volunteers. Journal of Clinical Pharmacology 22: 491, 1982
Barnes JN, Williams AJ, Tomson MJ, Toseland PA, Goodwin FJ. Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. British Medical Journal 290: 740, 1985
Barriere SL, Mills J. Ceforanide: antibacterial activity, pharmacology, and clinical efficacy. Pharmacotherapy 2: 322, 1982
Baudinet C, Henrard L, Quinaux N, Elallaf D, De Landsheere C, et al. Pharmacokinetics of mexiletine in renal insufficiency. Acta Cardiologica (Suppl. 25): 55, 1980
Bauer LA, Bauer SP, Blouin RA. The effect of acute and chronic renal failure on theophylline clearance. Journal of Clinical Pharmacology 22: 65, 1982
Beermann B, Groschinsky-Grind M. Clinical pharmacokinetics of diuretics. Clinical Pharmacokinetics 5: 221, 1980
Benet LZ. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. Journal of Pharmacokinetics and Biopharmaceutics 7: 1, 1979
Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 37: 1416, 1977
Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, et al. Drug prescribing in renal failure: dosing guidelines for adults. American Journal of Kidney Diseases 3: 155, 1983
Bergan T. Overview of acylureidopenicillin pharmacokinetics. Scandinavian Journal of Infectious Diseases 29 (Suppl.): 33, 1981
Bergan T. Review of the pharmacokinetics of mezlocillin. Journal of Antimicrobial Chemotherapy 11 (Suppl. C): 1, 1983
Bergan T, Orjavik O, Brodwall EK. Pharmacokinetics of cefapirin in patients with normal and impaired renal function. Arzneimittel-Forschung 10: 1773, 1981
Bergstrom RF, Kay DR, Harkcom TM, Wagner JG. Penicillamine kinetics in normal subjects. Clinical Pharmacology and Therapeutics 30: 404, 1981
Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone, and naloxone. Clinical Pharmacokinetics 1: 219, 1976
Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clinical Pharmacokinetics 3: 128, 1978
Bishop MJ, Hornbein TF. Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure. Anesthesiology 58: 384, 1983
Blachey JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Annals of Internal Medicine 95: 628, 1981
Blair AD, Burgess ED, Maxwell BM, Cutler RE. Sotalol kinetics in renal insufficiency. Clinical Pharmacology and Therapeutics 29: 457, 1981
Boerner U, Abbott S, Roe RL. The metabolism of morphine and heroin in man. Drug Metabolism Reviews 4: 39, 1975
Breimer DD, Jochemsen R. Clinical pharmacokinetics of hypnotic benzodiazepines. British Journal of Clinical Pharmacology 16: 2775, 1983
Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied disease. Drugs 24: 267, 1982
Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS. Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 12: 166, 1976
Brogden RN, Speight TM, Avery GS. Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 9: 251, 1975
Bullingham RE, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clinical Pharmacokinetics 8: 332, 1983
Bury RW, Becker GJ, Kincaid-Smith PS, Moulds RFW, Whitworth JA. Elimination of enoxacin in renal disease. Clinical Pharmacology and Therapeutics 41: 434–438, 1987
Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic uses. Drugs 22: 257, 1981
Campoli-Richards DM, Clissold SP. Famotidine: pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 32: 197–221, 1986
Carmine AA, Brogden RN, Heel RC, Romankiewicz JA, Speight TM, et al. Moxalactam (latamoxef): a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 26: 279, 1983
Carter BL. Labetalol. Drug Intelligence and Clinical Pharmacy 17: 704, 1983
Chaffman M, Brogden RN. Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 29: 387, 1985
Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS. Auranofin: a preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs 27: 378, 1984a
Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS. Indapamide: a review of pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 28: 189, 1984b
Chennavasin P, Brater DC. Nomograms for drug use in renal disease. Clinical Pharmacokinetics 6: 193, 1981
Christensen JH, Andreasen F, Jansen J. Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. Acta Anaesthesiologica Scandinavica 27: 513, 1983
Clark J, Hochman R, Rolla AR, Thomas S, Miller DG, et al. Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure. Clinical and Experimental Dialysis and Apheresis 7: 177, 1983
Cohn JN, Buke LP. Nitroprusside. Annals of Internal Medicine 91: 752, 1979
Conard GJ, Ober RE. Metabolism of flecainide. American Journal of Cardiology 53: 41B, 1984
Conklin JD. The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiotics and Chemotherapy 25: 233, 1978
Conner CS. Atracurium and vercuronium: two unique neuromuscular blocking agents. Drug Intelligence and Clinical Pharmacy 18: 714, 1984
Cooper DS. Antithyroid drugs. New England Journal of Medicine 311: 1353, 1984
Craig WA, Gudmauadsson S, Reich RM. Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy. Pharmacotherapy 3: 305, 1983
Cronnelly R, Stanski DR, Miller RD. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology 51: 22, 1979
Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. Clinical Pharmacology and Therapeutics 28: 78, 1980
Crooke ST, Comis RL, Einhorn LH, Strong JE, Broughton A, et al. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an IV bolus. Cancer Treatment Reports 61: 1631, 1977
Crooke ST, Prestakayo AW. Bleomycin pharmacokinetics in patients with varying renal function. Cancer Research 18: 286, 1977
Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clinical Pharmacokinetics 6: 135, 1981
Czerwinski A, Federson J. Pharmacokinetics of cefamandole in patients with renal impairment. Antimicrobial Agents and Chemotherapy 15: 161, 1979
Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clinical Pharmacokinetics 8: 17, 1983
Dawling S, Lynn K, Rosser R. Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clinical Pharmacology and Therapeutics 32: 322, 1982
Dayton PG, Perel JM. The metabolism of probenecid in man. Annals of the New York Academy of Sciences 179: 399, 1971
Deny JE. Evaluation of cefaclor. American Journal of Hospital Pharmacy 38: 54, 1981
Doller HJ. Levodopa pharmacokinetics. Drug Metabolism and Disposition 6: 164, 1978
Doluiso JT. Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. Reviews of Infectious Diseases 4: S333, 1982
Don HG, Dieppa RA, Taylor P. Narcotic analgesics in anuric patients. Anesthesiology 42: 745, 1976
Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, et al. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 31: 860–864, 1987
Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. Kidney International 25: 942, 1984
Eadie MJ. Anticonvulsant drugs: an update. Drugs 27: 328, 1984
Edwards DJ, Svensson CK, Visco JP, Lalka D. Clinical pharmacokinetics of pethidine: 1982. Clinical Pharmacokinetics 7: 421, 1982
Ehrsson H, Hassan M, Ehrnebo M, Beran M. Busulfan kinetics. Clinical Pharmacology and Therapeutics 34: 86, 1983
Eiriksson CE, Brogden RN. Lorcainide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 27: 279, 1983
Eliopoulos GM, Moellering RC. Azlocillin, mezlocillin and piperacillin: new broad spectrum penicillins. Annals of Internal Medicine 97: 755, 1982
Estes JW. Clinical pharmacokinetics of heparin. Clinical Pharmacokinetics 5: 204, 1980
Ettinger B, Oldroyd NO, Sorgel F. Triamterene nephrolithiasis. Journal of the American Medical Association 244: 2443, 1980
Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61: 699, 1984
Faulkner RD, Senekjian HO, Lee CS. Hemodialysis of doxepin and desmethyldoxepin in uremic patients. Artificial Organs 8: 151, 1984
Feldman JM. Glyburide: a second generation sulfonylurea hypoglycemic agent. Pharmacotherapy 5: 43, 1985
Fillastre JP, Leroy A, Baudoin C, Humbert G, Swabb EA, et al. Pharmacokinetics of aztreonam in patients with chronic renal failure. Clinical Pharmacokinetics 10: 91, 1985
Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, et al. Intravenous cyclosporine kinetics in renal failure. Clinical Pharmacology and Therapeutics 34: 638, 1983
Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clinical Pharmacokinetics 7: 93, 1982
Forsman A, Ohman R. Pharmacokinetic studies on haloperidol in man. Current Therapeutic Research 20: 319, 1976
Frishman W. Atenolol and timolol, two new systemic β-adrenoreceptor antagonists. New England Journal of Medicine 306: 1456, 1982
Frishman WH. Nadolol: a new beta adrenoreceptor antagonist. New England Journal of Medicine 305: 678, 1981
Fung DL, Eisele JH. Fentanyl pharmacokinetics in awake volunteers. Journal of Clinical Pharmacology 20: 652, 1980
Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. Annals of Internal Medicine 90: 338, 1979
Gaginella TS, Bauman JH. Ranitidine hydrochloride. Drug Intelligence and Clinical Pharmacy 17: 873, 1983
Galeazzi RL, Gugger M, Weidmann P. Beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man. Kidney International 15: 661, 1979
Gambertoglio JG, Alexander DP, Barriere SL. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis. Antimicrobial Agents and Chemotherapy 26: 845, 1984
Gambertoglio JG, Laver RM. Use of neuropsychiatric drugs. In Anderson & Schrier (Eds) Clinical use of drugs in patients with kidney and liver disease, pp. 276–295, W.B. Saunders, Philadelphia, 1981
Gasser TC, Ebert SC, Graverson PH, Madsen PO. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrobial Agents and Chemotherapy 31: 709–712, 1987
Gault MH, Vasdev SC, Longerich LL. Endogenous digoxin-like substances and combined hepatic and renal failure. Annals of Internal Medicine 101: 567, 1984
George CF. Amiloride handling in renal failure. British Journal of Clinical Pharmacology 9: 94, 1980
Gibson TP, Atkinson AJ, Matusik E. Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney International 12: 422, 1977a
Gibson TP, Demetriades JL, Bland JA. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Abstracts. American Journal of Medicine 78: 54, 1985
Gibson TP, Giacomini KM, Briggs WA. Pharmacokinetics of d-propoxyphene in anephric patients. Clinical Pharmacology and Therapeutics 21: 103, 1977b
Gillis AM, Kates RE. Clinical pharmacokinetics of the newer antiarrhythmic agents. Clinical Pharmacokinetics 9: 375, 1984
Glazko AJ, Dill WA, Young RM. Metabolic disposition of diphenhydramine. Clinical Pharmacology and Therapeutics 16: 1066, 1974
Gnann JW, Barton NH, Whitley RJ. Acyclovir mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy 3: 275, 1983
Gormley PE, Bull JM, LeRoy AF. Kinetics of cisdichlorodiammineplatinum. Clinical Pharmacology and Therapeutics 25: 351, 1979
Graves PE, Fenster PE, MacFarland RT, Marcus FI, Perrier D. Kinetics of digitoxin and the bis-monodigitoxosides of digitoxigenin in renal insufficiency. Clinical Pharmacology and Therapeutics 36: 607, 1984
Graybill JR, Craven PC. Antifungal drugs used in systemic mycoses. Drugs 25: 41, 1983
Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clinical Pharmacokinetics 6: 89, 1981
Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Clinical pharmacokinetics of the newer benzodiazepines. Clinical Pharmacokinetics 8: 233, 1983
Greenblatt DJ, Shader RI, MacLeod SM. Clinical pharmacokinetics of chlordiazepoxide. Clinical Pharmacokinetics 3: 381, 1978
Greenblatt DJ, Shader RI. Clinical use of the benzodiazepines. Rational Drug Therapy 15: 1, 1981
Grochow LB, Colvin M. Clinical pharmacokinetics of cyclophosphamide. Clinical Pharmacokinetics 4: 380, 1979
Guay DR. Netilmicin. Drug Intelligence and Clinical Pharmacy 17: 83, 1983
Gugler R. Clinical pharmacokinetics of hypolipidaemic drugs. Clinical Pharmacokinetics 3: 425, 1978
Hallynek T, Soep HH, Dehli L. Influence of age and renal disease on aminoglycoside dosage. Journal of Antimicrobial Chemotherapy 8 (Suppl. A): 1, 1981
Halstenson CE, Abraham PA, Opsah IJA, Chremos AN, Keane WF, et al. Disposition of famotidine in renal insufficiency. Journal of Clinical Pharmacology 27: 782–787, 1987
Halstenson CE, Matzke GR. Bumetanide: a new loop diuretic. Drug Intelligence and Clinical Pharmacy 17: 786, 1983
Hande K, Reed E, Chabner B. Allopurinol kinetics. Clinical Pharmacology and Therapeutics 23: 598, 1978
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. American Journal of Medicine 76: 47, 1984
Hanna WT, Knauss S, Regester RF. Renal disease after mitomycin C therapy. Cancer 48: 2583, 1981
Hansten PD. Potassium supplement interactions. Drug Interactions Newsletter 2: 1, 1982
Harber F, Egger H-J, Weidekamm E, Dubach UC, Frey FJ, et al. Pharmacokinetics of carumonam in patients with renal insufficiency. Antimicrobial Agents and Chemotherapy 29: 116–121, 1986
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, et al. Metoclopramide: an updated review of its pharmacologic properties and clinical use. Drugs 25: 451, 1983
Hartigh JD, McVie JG, Van Oort WJ, Pinedo HM. Pharmacokinetics of mitomycin C in humans. Cancer Research 43: 5017, 1983
Hasegawa GR. Tocainide: a new oral antiarrhythmic. Drug Intelligence and Clinical Pharmacy 19: 514, 1985
Hasegawa J, Lin ET, Williams RL, Sorgel F, Benet LZ. Pharmacokinetics of triamterene and its metabolite in man. Journal of Pharmacokinetics and Biopharmaceutics 10: 507, 1982
Hasenfuss G, Schäfer-Korting M, Knauf H, Mutschler E, Just H. Pharmacokinetics of carteolol in relation to renal function. European Journal of Clinical Pharmacology 29: 461–465, 1985
Heany D, Eknoyan G. Minocycline and doxycycline kinetics in chronic renal failure. Clinical Pharmacology and Therapeutics 24: 233, 1978
Heel RC, Brogden RN, Speight TM, Avery GS. Butorphanol: a review of its pharmacologic properties and therapeutic efficacy. Drugs 16: 473, 1978
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Sternson LA. Clinical kinetics of intact cisplatin and some related species. Clinical Pharmacology and Therapeutics 29: 658, 1981
Hirsch MD, Swartz MN. Antiviral agents. New England Journal of Medicine 302: 903, 949, 1980
Höffler D, Schäfer I, Koeppe P, Sörgel F. Pharmacokinetics of Pefloxacin in normal and impaired renal function. Arzneimittel-Forschung 38: 739–743, 1988
Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clinical Pharmacokinetics 9: 511, 1984
Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Guanabenz: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 26: 212, 1983
Holmes B, Heel RC. Flecainide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 1, 1985
Holmes B, Richards DM, Brogden RN, Heel RC. Piperacillin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 28: 375, 1984
Hopefl AW. Aztreonam — an overview. Drug Intelligence and Clinical Pharmacy 19: 171, 1985
Houghton GW, Dennis MJ, Gabriel R. Pharmacokinetics of metronidazole in patients with varying degrees of renal failure. British Journal of Clinical Pharmacology 19: 203, 1985
Houston MC. Clonidine hydrochloride: review of pharmacological and clinical aspects. Progress in Cardiovascular Diseases 23: 337, 1981
Inturrisi CE. Disposition of narcotics in patients with renal disease. American Journal of Medicine 62: 528, 1977
Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. New England Journal of Medicine 309: 1094, 1983
Kampf D, Shurig R, Korsukewitz I, Bruckner O. Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency. Antimicrobial Agents and Chemotherapy 20: 741, 1981
Kampmann JP, Hansen JM. Clinical pharmacokinetics of antithyroid drugs. Clinical Pharmacokinetics 6: 401, 1981
Kantor TG. Ibuprofen. Annals of Internal Medicine 91: 877, 1979
Kates RE. Calcium antagonists: pharmacokinetic properties. Drugs 25: 113, 1983
Kelly JG, O’Malley K. Clinical pharmacokinetics of oral anticoagulants. Clinical Pharmacokinetics 4: 1, 1979
Kirch W, Gorg ER. Clinical pharmacokinetics of atenolol — a review. European Journal of Drug Metabolism and Pharmacokinetics 7: 81, 1982
Kirch W, Rämsch KD, Dührsen U, Ohnhaus EE. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. International Journal of Clinical Pharmacology Research 4: 381–384, 1984
Kirch W, Rose I, Demers HG, Leopold G, Pabst J, et al. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clinical Pharmacokinetics 13: 110–117, 1987
Knepshield JH, Winchester JF. Hemodialysis and hemoperfusion for drugs and poisons. Transactions of the American Society of Artificial Internal Organs 28: 666, 1982
Koeppe P, Höffler D, Strobel K. Pharmacokinetics and dosage recommendations of carumonam in renal failure. Arzneimittel-Forschung 37: 65–69, 1987
Konishi K, Ozawa Y. Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis. Antimicrobial Agents and Chemotherapy 26: 647, 1984
Kradjan WA, Martin TR, Delaney CJ, Blair AD, Cutler RE. Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure. Nephron 32: 40, 1982
Kramer HJ, Pennig J, Klingmuller D, Kipnowski J, Glanzer K, et al. Digoxin-like immunoreacting substances in the serum of patients with chronic uremia. Nephron 40: 297, 1985
Kucers A. Chloramphenicol, erythromycin, vancomycin, tetracyclines. Lancet 2: 425, 1982
Kusumi R, Metzler C, Fass R. Pharmacokinetics of spectinomycin in volunteers with renal insufficiency. Chemotherapy 27: 95, 1981
Lange K. Nephropathy induced by D-penicillamine. Contributions to Nephrology 10: 63, 1978
Lant A. Diuretics: clinical pharmacology and therapeutic use. Drugs 29: 57, 162, 1985
Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, et al. Pharmacokinetics of Cimetidine and its sulfoxide metabolite during hemodialysis. European Journal of Clinical Pharmacology 21: 325, 1982
Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clinical Pharmacokinetics 9: 136, 1984
Latos DS, Bryan CS, Stone WJ. Carbenicillin therapy in patients with normal and impaired renal function. Clinical Pharmacology and Therapeutics 17: 692, 1975
Lebovitz HE. Glipizide: a second generation sulfonylurea hypoglycemic agent. Pharmacotherapy 5: 63, 1985
Lecaillon JB, Souppart C, Schroeller JP, Humbert G, Massias P. Sulfinpyrazone kinetics after intravenous and oral administration. Clinical Pharmacology and Therapeutics 26: 611, 1979
Lee CS, Marbury TC, Perchalski RT, Wilder BJ. Pharmacokinetics of primidone elimination by uremic patients. Journal of Clinical Pharmacology 22: 301, 1982
Lehmann CR, Heironimus JD, Collins CB, O’Neil TJ, Pierson WP, et al. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clinical Pharmacology and Therapeutics 37: 284, 1985
Leroy A, Humbert G, Godin M, Finllastre JP. Pharmacokinetics of cefadroxil in patients with impaired renal function. Journal of Antimicrobial Chemotherapy 10 (Suppl. B): 39, 1982
Levy G. Pharmacokinetics of salicylate in man. Drug Metabolism Reviews 9: 13, 1979
Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clinical Pharmacology and Therapeutics 37: 301, 1985
Lipner HI, Ruzany F, Dasgupta M. The behavior of carbenicillin as a nonreabsorbable anion. Journal of Laboratory and Clinical Medicine 86: 183, 1975
Loo JC, Midha KK, McGilveray IJ. Pharmacokinetics of chlorpromazine in normal volunteers. Communications in Psychopharmacology 4: 121, 1980
Lorber A. Monitoring gold plasma levels in rheumatoid arthritis. Clinical Pharmacokinetics 2: 127, 1977
Lowenthal DT, Hobbs D, Affrime MB. Prazosin kinetics and effectiveness in renal failure. Clinical Pharmacology and Therapeutics 27: 779, 1980
Ludden TM, McNay JL, Shephard A, Lin MS. Clinical pharmacokinetics of hydralazine. Clinical Pharmacokinetics 7: 185, 1982
Lydiard RB, Gelenberg AJ. Hazards and adverse effects of lithium. Annual Review of Medicine 33: 327, 1982
Lyon JA. Cefoperazone. Drug Intelligence and Clinical Pharmacy 17: 7, 1983
Maher JF. Pharmacokinetics in patients with renal failure. Clinical Nephrology 21: 39, 1984
Malacoff RF, Finkelstein FO, Andriole VI. Effect of peritoneal dialysis on serum levels of tobramycin and lincomycin. Antimicrobial Agents and Chemotherapy 8: 574, 1975
Mandelli M, Tognoni G, Garattini S. Clinical pharmacokinetics of diazepam. Clinical Pharmacokinetics 3: 72, 1978
Marbury TC, Lee CS, Bruni J, Wilder BJ. Hemodialysis of valproic acid in uremic patients. Dialysis and Transplantation 9: 961, 1980
Marcantonio LA, Auld WHR, Murdoch WR, Purohit R, Skellern GG, et al. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. British Journal of Clinical Pharmacology 15: 245, 1983
Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clinical Pharmacokinetics 8: 422, 1983
Matteo RS, Nichitateno K, Pua EK, Spector S. Pharmacokinetics of d-tubocurarine in man. Anesthesiology 52: 335, 1980
Matzke GR, Keane WF. Cefsulodin pharmacokinetics in patients with various degrees of renal function. Antimicrobial Agents and Chemotherapy 23: 369, 1983
McAllister CJ, Scowden EB, Stone WJ. Toxic psychosis induced by phenothiazine administration in patients with chronic renal failure. Clinical Nephrology 10: 191, 1978
McAllister RG, Hamann SR, Blouin RA. Pharmacokinetics of calcium-entry blockers. American Journal of Cardiology 55: 30B, 1985
Medical Letter. Pentamidine for Pneumocystis carinii pneumonia. 27: 6, 1985
Meyer RD. Amikacin. Annals of Internal Medicine 95: 328, 1981
Miller RD. Vercuronium: a new nondepolarizing neuromuscular blocking agent. Pharmacotherapy 4: 238, 1984
Miller RD, Maheo RS, Benet LZ. The pharmacokinetics of d-tubocurarine with and without renal failure. Journal of Pharmacology and Experimental Therapeutics 202: 1, 1977
Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Annals of Internal Medicine 94: 343, 1981
Morrison G, Chiang ST, Koepke HH, Walker BR. Effect of renal impairment and hemodialysis on lorazepam kinetics. Clinical Pharmacology and Therapeutics 35: 646, 1984
Morsil DN, Brown RD. Acetazolamide and symptomatic metabolic acidosis in mild renal failure. British Medical Journal 283: 1527, 1981
Mulley BA, Parr GD, Rye RM. Pharmacokinetics of chlorthalidone. European Journal of Pharmacology 17: 203, 1980
Munch R, Luthy R, Blaser J, Siegenthaler W. Human pharmacokinetics and CSF penetration of clavulanic acid. Journal of Antimicrobial Chemotherapy 8: 29, 1981
Murray TG, Chiang ST, Koepke HH. Renal disease, age and oxazepam kinetics. Clinical Pharmacology and Therapeutics 30: 805, 1981
Myhre F, Rugstad HE, Hansen T. Clinical pharmacokinetics of methyldopa. Clinical Pharmacology and Therapeutics 7: 221, 1982
Naesdal J, Andersson T, Bodemar G, Larsson R, Regårdh C-G, et al. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clinical Pharmacology and Therapeutics 40: 344–351, 1986
Nanlin S, Jessup K, Floyd M, Wang T, Van Buren CT, et al. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients. Transplantation 29: 290, 1980
Nauta EH, Mattie H. Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects. Clinical Pharmacology and Therapeutics 20: 98, 1976
Nelson E. Rate of metabolism of tolbutamide in test subjects with liver disease or impaired renal function. American Journal of the Medical Sciences 248: 657, 1964
Neu HC. Amoxicillin. Annals of Internal Medicine 90: 356, 1979
Neu HC. Amdinocillin: a novel penicillin. Antibacterial activity, pharmacology and clinical use. Pharmacotherapy 5: 1, 1985
Nickander R, McMahon FG, Ridolfo AS. Nonsteroidal antiinflammatory drugs. Annual Review of Pharmacology and Toxicology 19: 469, 1979
Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schafer-Korting M, et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. European Journal of Clinical Pharmacology 24: 661, 1983
Noone P. Sisomicin, netilmicin and dibekacin: a review of their antibacterial activity and therapeutic use. Drugs 27: 548, 1984
Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clinical Neuropharmacology 7: 35, 1984
Ochs HR, Greenblatt DJ, Woo E. Clinical pharmacokinetics of quinidine. Clinical Pharmacokinetics 5: 150, 1980
Ogilvie RI. Clinical pharmacokinetics of theophylline. Clinical Pharmacokinetics 3: 267, 1978
Ohkawa M, Takamae K, Shimamura M, Kuroda K, Awazu S. Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function. Chemotherapy 27: 149, 1981
Oltmanns D, Pottage A, Endell W. Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction. European Journal of Clinical Pharmacology 25: 787, 1983
Owellen RJ, Roat MA, Hains FO. Pharmacokinetics of vinblastine and vincristine in humans. Cancer Research 37: 2603, 1977
Parry MF, Neu HC. Pharmacokinetics of ticarcillin in patients with abnormal renal function. Journal of Infectious Diseases 133: 46, 1976
Patel R, Welling PG. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clinical Pharmacokinetics 5: 403, 1980
Payne JP. The clinical pharmacology of pentazocine. Drugs 5: 1, 1973
Payton CD, Fox JG, Pauleau NF, Boulton-Jones JM, Ioannides C, et al. The single dose pharmacokinetics of bisoprolol (10mg) in renal insufficiency: the clinical significance of balanced clearance. European Heart Journal 8 (Suppl. M): 15–22, 1987
Pearson RM. Pharmacokinetics and response to diazoxide in renal failure. Clinical Pharmacokinetics 2: 198, 1977
Pechere J, Dugal R. Clinical pharmacokinetics of aminoglycoside antibiotics. Clinical Pharmacokinetics 4: 170, 1979
Peets EA, Jackson M, Symchowics S. Metabolism of chlorpheniramine maleate in man. Journal of Pharmacology and Experimental Therapeutics 180: 464, 1972
Penry JK, Newmark ME. The use of antiepileptic drugs. Annals of Internal Medicine 90: 207, 1979
Pontzer RE, Kaye D. Cefonicid: a long acting, second generation cephalosporin. Pharmacotherapy 4: 325, 1984
Procci WR. Mania during maintenance hemodialysis successfully treated with oral lithium carbonate. Journal of Nervous and Mental Diseases 164: 355, 1977
Quintiliani R, Nightingale CH. Cefazolin. Annals of Internal Medicine 89: 650, 1978
Rabkin R, Simon NM, Steiner S. Effect of renal disease on renal uptake and excretion of insulin in man. New England Journal of Medicine 282: 182, 1970
Rahn KH. The influence of renal function on plasma levels, urinary excretion, metabolism and antihypertensive effects of guanethidine in man. Clinical Nephrology 1: 14, 1973
Ralph ED. Clinical pharmacokinetics of metronidazole. Clinical Pharmacokinetics 8: 43, 1983
Ramzam MI, Shanks CA, Triggs EJ. Gallamine disposition in surgical patients with chronic renal failure. British Journal of Clinical Pharmacology 12: 141, 1981a
Ramzam MI, Somogyi AA, Walker JS, Shanks CA, Triggs EJ. Clinical pharmacokinetics of the nondepolarizing muscle relaxants. Clinical Pharmacokinetics 6: 25, 1981b
Rapeport WG. Clinical pharmacokinetics of bretylium. Clinical Pharmacokinetics 10: 248, 1985
Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clinical Pharmacology and Therapeutics 28: 769, 1980
Reeves D. Sulphonamides and trimethoprim. Lancet 2: 370, 1982
Regardh CG, Johnsson G. Clinical pharmacokinetics of metoprolol. Clinical Pharmacokinetics 5: 557, 1980
Reidenberg MM, Drayer DE. Drug therapy in renal failure. Annual Review of Pharmacology and Toxicology 20: 45, 1980
Rhymer AR. Sulindac. Clinics in Rheumatic Diseases 5: 553, 1979
Richards DM, Brogden RN. Ceftazidime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29: 105, 1985
Richards DM, Heel RC. Ceftizoxime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29: 281, 1985
Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27: 469, 1984
Richens A. Clinical pharmacokinetics of Phenytoin. Clinical Pharmacokinetics 4: 153, 1979
Rimmer EM, Richens A. An update on sodium valproate. Pharmacotherapy 5: 171, 1985
Ristuccia AM, Cunha BA. An overview of amikacin. Therapeutic Drug Monitoring 7: 12, 1985
Roberts AP, Eastwood JB, Gower PE, Fenton CM, Curtis JR. Serum and plasma concentration of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance hemodialysis patients and normal subjects. European Journal of Clinical Pharmacology 14: 435, 1978
Roberts C. Clinical pharmacokinetics of ranitidine. Clinical Pharmacokinetics 9: 211, 1984
Roth T, Roehrs TA, Zonck FJ. Pharmacology and hypnotic efficacy of triazolam. Pharmacotherapy 3: 137, 1983
Rudnick M, Morrison G, Walker G. Renal failure, hemodialysis and nafcillin kinetics. Clinical Pharmacology and Therapeutics 20: 413, 1976
Rumore MM. Clinical pharmacokinetics of chlorpheniramine. Drug Intelligence and Clinical Pharmacy 18: 701, 1984
Sandoz M, Vandel S, Vandel B, Bonin B, Hory B, et al. Metabolism of amitriptyline in patients with chronic renal failure. European Journal of Clinical Pharmacology 26: 227, 1984
Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate. Clinical Pharmacokinetics 9: 239, 1984
Sheehan J, White A, Wilson R. Hazards of phenothiazines in chronic renal failure. Irish Medical Journal 75: 335, 1982
Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clinical Pharmacokinetics 3: 1, 1978
Shen DD, Cunningham JL, Shudo I. Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharmaceuticals and Drug Disposition 1: 133, 1980
Sherrard DJ, Goldberg AB, Haas LB, Brunzell JB. Chronic clofibrate therapy in maintenance hemodialysis patients. Nephron 25: 219, 1960
Shionori H, Ikeda Y, Kimura K, Miyakawa T, Kaneko Y. Pharmacodynamics and pharmacokinetics of single dose ramipril in hypertensive patients with various degrees of renal function. Current Therapeutic Research 40: 74–85, 1986
Siegal D. Tetracyclines: a new look at old antibiotics. New York State Journal of Medicine 78: 950, 1115, 1978
Singh BN, Thoden WR, Ward A. Acebutolol: a review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs 29: 531, 1985
Skillman TG, Feldman JM. The pharmacology of sulfonylureas. American Journal of Medicine 70: 361, 1981
Slaughter RL, Cerra FB, Koup JR. Effect of hemodialysis on total body clearance of chloramphenicol. American Journal of Hospital Pharmacy 37: 1083, 1980
Smith BR, LeFrock J. Amoxicillin-potassium clavulanate: a novel β-lactamase inhibitor. Drug Intelligence and Clinical Pharmacy 19: 415, 1985
Solomon AE, Buggs JD, McGleachey R. The administration of cephradine to patients with normal and impaired renal function. British Journal of Clinical Pharmacology 2: 443, 1975
Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clinical Pharmacokinetics 8: 463, 1983
Somogyi AA, Shanks CA, Triggs EA. The effects of renal failure on the disposition and neuromuscular blocking effects of pancuronium bromide. European Journal of Clinical Pharmacology 12: 23, 1977
Spark RF, Dickstein G. Bromocriptine and endocrine disorders. Annals of Internal Medicine 90: 949, 1979
Stanaszek WF, Kellerman D, Brogden RN, Romankiewicz JA. Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25: 339, 1983
Stein G, Kunze M, Zaumseil J, Traeger A. Pharmacokinetics of indomethacin and indomethacin metabolites administered continually to patients with healthy and damaged kidneys. International Journal of Clinical Pharmacology and Biopharmaceutics 15: 470, 1977
Stone WJ, Walle T. Massive propranolol metabolic retention during maintenance hemodialysis. Clinical Pharmacology and Therapeutics 28: 448, 1980
Szeto HH, Inturrisi CE, Houde R, Reidenberg M. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Annals of Internal Medicine 86: 738, 1977
Tartaglione TA, Polk RE. Review of the new second generation cephalosporins: cefonicid, ceforanide and cefuroxime. Drug Intelligence and Clinical Pharmacy 19: 188, 1985
Thompson RL, Wright AJ. Cephalosporin antibiotics. Mayo Clinic Proceedings 58: 79, 1983
Tien AN, Bjornson J. Heparin elimination in uremic patients on hemodialysis. Scandinavian Journal of Haematology 17: 29, 1977
Tilstone WJ, Dargie H, Dargie EN. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal dysfunction. Clinical Pharmacology and Therapeutics 16: 322, 1974
Van Scoy RE, Wilson WR. Antimicrobial agents in patients with renal insufficiency. Mayo Clinic Proceedings 58: 246, 1983
Van Tyle JH. Ketoconazole mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy 4: 343, 1984
Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clinical Pharmacokinetics 8: 297, 1983
Vohringer HF, Rietbrock N. Digitalis therapy in renal failure with special regard to digitoxin. International Journal of Clinical Pharmacology, Therapy and Toxicology 19: 175, 1981
Waller ES. Pharmacokinetic principles of lidocaine dosing in relation to disease state. Journal of Clinical Pharmacology 21: 181, 1981
Walstad RA, Nilsen OG, Berg KJ. Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. European Journal of Clinical Pharmacy 24: 391, 1983
Ward A, Heel RC. Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic uses. Drugs 28: 426, 1984
Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clinical Pharmacokinetics 4: 287, 1976
Welling PG, Craig W. Pharmacokinetics of intravenous erythromycin. Journal Pharmaceutical Sciences 67: 1057, 1978
Wenk M, Vozeh S, Follath F. Serum level monitoring of antibacterial drugs. Clinical Pharmacokinetics 9: 475, 1984
Whelton A, Stout RL, Delgado FA. An azlocillin closing nomogram for renal insufficiency. Journal of Antimicrobial Chemotherapy 11 (Suppl. B): 97, 1983
White NJ. Clinical pharmacokinetics of antimalarial drugs. Clinical Pharmacokinetics 10: 187, 1985
Wise R. Penicillins and cephalosporins: antimicrobial and pharmacological properties. Lancet 2: 140, 1982
Wood AJ, Vestal RE, Spannuth CL. Propranolol disposition in renal failure. British Journal of Clinical Pharmacology 10: 561, 1980
Wright AJ, Wilkowske CJ. The penicillins. Mayo Clinic Proceedings 58: 21, 1983
Wu MJ, Ing TS, Soung S, Daugirdas JT, Hano JE, et al. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clinical Nephrology 17: 19, 1982
Zsotér TT, Johnson GE, DeVeber GA. Excretion and metabolism of reserpine in renal failure. Clinical Pharmacology and Therapeutics 14: 325, 1973
Author information
Authors and Affiliations
Additional information
This article was first published as Appendix D in Speight T.M. (Ed.) Avery’s drug treatment, 3rd ed., ADIS press, Auckland, 1987. The table will be updated and republished in the Journal each year.
Rights and permissions
About this article
Cite this article
Bennett, W.M. Guide to Drug Dosage in Renal Failure. Clin-Pharmacokinet 15, 326–354 (1988). https://doi.org/10.2165/00003088-198815050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198815050-00005